BAK1 and adenocarcinoma: Future studies also need to characterize BAK1, FIS1 and SFN protein expression profiles in Barrett’s and adenocarcinoma patients and correlate such expression profiles with surrogate markers associated with mitochondrial dysfunction to gain further insight into potential therapeutic or prognostic roles that these mitochondrial markers may encompass.